Aperam

Q225 in line but the outlook confirms the lack of momentum

05/08/25 -"Aperam reported expected results for Q2/H125, showing improvement over Q1 primarily due to effective cost management, despite a subdued market environment. However, Q3 is anticipated to decline due ..."

PDF page sample
Pages
59
Language
English
Published on
05/08/25
Download
You may also be interested by these reports :
06/08/25
After long-term trading EBIT guidance upgrade and planned cost savings were announced during H1 25 production release, expectations of strong ...
06/08/25
A solid 1Q25/26 EBITDA slightly below consensus – Unchanged guidance
05/08/25
Aperam reported expected results for Q2/H125, showing improvement over Q1 primarily due to effective cost management, despite a subdued market ...
05/08/25
High metal and sulphuric acid prices lifted 3Q EBT to the high end of expectations – Cautious full year guidance

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO